The Trump administration is proposing major cuts to federal health spending, including a more than 12% reduction to HHS.

Aspergillosis diagnoses increased significantly among US adults between 2013 and 2023, with geographic and demographic variations.

A subgroup of patients with SSc who exhibit a severe GI phenotype were associated with longer disease duration, ACA positivity, PAH, and worse quality of life.

Treatment with upadacitinib is safe and effective for adults and adolescents with nonsegmental vitiligo, according to a study from AAD 2026.

Ixekizumab plus tirzepatide shows significant benefits for outcomes in psoriatic arthritis vs IXE alone in adults with overweight or obesity.

An update to the guidelines for urticaria management was published, involving collaboration from various international professional societies.

Interferon injection therapy significantly improves the number of common warts on the hands and feet compared with conventional cryotherapy.

Tildrakizumab, risankizumab, and guselkumab are effective for psoriasis in high-impact areas, though effectiveness varies across affected sites.

While the overall rate of pediatric admissions for dermatologic conditions has declined from 2012 to 2022, significant disparities remain.

The EPA announced plans to add microplastics and leftover medications to its list of priority pollutants in drinking water.

Patients with dermatomyositis in the US experience substantial variability in treatment, high glucocorticoid exposure, and significant healthcare utilization.

A new vaccine from companies Pfizer and Valneva meant to prevent Lyme disease may be one step closer to approval.